Beam Therapeutics (BEAM) Profit After Tax (2019 - 2026)

Beam Therapeutics (BEAM) has reported Profit After Tax for 8 consecutive years, with -$96.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax rose 10.92% year-over-year to -$96.5 million; the TTM figure through Mar 2026 stood at $147.8 million (up 138.15% YoY), while the FY2025 annual figure was -$79.6 million, up 78.88% from the prior year.
• Profit After Tax eased to -$96.5 million in Q1 2026 per BEAM's latest filing, from $244.7 million in the prior quarter.
• Across five years, Profit After Tax topped out at $244.7 million in Q4 2025 and bottomed at -$110.1 million in Q3 2022.
• Historically, Profit After Tax has averaged -$44.4 million across 5 years, with a median of -$91.1 million in 2024.
• Annual changes were most pronounced in 2022 — Profit After Tax slumped 291.42% — and 2023, when it soared 503.91%.
• Beam Therapeutics' Profit After Tax stood at -$36.1 million in 2022, then jumped by 503.91% to $145.8 million in 2023, then slumped by 162.7% to -$91.4 million in 2024, then soared by 367.66% to $244.7 million in 2025, then tumbled by 139.43% to -$96.5 million in 2026.
• Business Quant data shows BEAM's Profit After Tax at -$96.5 million in Q1 2026, $244.7 million in Q4 2025, and -$200000.0 in Q3 2025.